| Joseph Paul Dileo, DPM | |
|
42388 Pelican Professional Park, Hammond, LA 70403 | |
| (985) 542-6251 | |
| Not Available |
| Full Name | Joseph Paul Dileo |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 25 Years |
| Location | 42388 Pelican Professional Park, Hammond, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396774824 | NPI | - | NPPES |
| PD264R | Other | LA | DPM LICENSE # |
| 7289375 | Other | LA | AETNA US HEALTHCARE |
| 28584 | Other | LA | LA CONTROL # |
| 1120707 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213EP1101X | Podiatrist - Primary Podiatric Medicine | PD264R (Louisiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| North Oaks Medical Center, L L C | Hammond, LA | Hospital |
| Lallie Kemp Medical Center | Independence, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lallie Kemp Medical Ctr | 0345238903 | 37 |
| Internal Medicine Clinic Of Tangipahoa, Llc | 9234034778 | 20 |
News Archive
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO.
Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.
› Verified 3 days ago
| Provider Name | Internal Medicine Clinic Of Tangipahoa, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1588678494 PECOS PAC ID: 9234034778 Enrollment ID: O20031206000015 |
News Archive
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO.
Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.
› Verified 3 days ago
| Provider Name | Lallie Kemp Medical Ctr |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1558303420 PECOS PAC ID: 0345238903 Enrollment ID: O20040503001188 |
News Archive
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO.
Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph Paul Dileo, DPM 42388 Pelican Professional Park, Hammond, LA 70403 Ph: (985) 542-6251 | Joseph Paul Dileo, DPM 42388 Pelican Professional Park, Hammond, LA 70403 Ph: (985) 542-6251 |
News Archive
A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.
mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity in women with ASC-US or LSIL cytology results.
Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,592,441 to Rosetta Genomics. The patent relates to human microRNA miR-193b, as well as to complementary probes and vectors. This is the third patent issued to Rosetta Genomics by the USPTO.
Sydney researchers have made a major breakthrough that will lead to a greater understanding of the causes of and treatments for neurodegenerative diseases.
› Verified 3 days ago
Allen's Podiatry Clinic Podiatrist Medicare: Medicare Enrolled Practice Location: 16026 Doctors Blvd, Hammond, LA 70403 Phone: 985-340-0099 Fax: 985-340-1130 | |
Dr Rene J Hymel Dpm Llc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2101 Robin Ave Ste 11, Hammond, LA 70403 Phone: 985-796-2218 Fax: 985-796-8667 | |
John Christopher Allen, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 16026 Doctor's Boulevard, Hammond, LA 70403 Phone: 985-340-0099 Fax: 985-340-1130 | |
John Lode, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 21051 Old Covington Hwy, Hammond, LA 70403 Phone: 985-345-6341 Fax: 866-343-8616 |